P53: Its alteration and gallbladder cancer

European Journal of Cancer Prevention

Volumn 20, Issue 2, 2011, Pages 77-85

  Rai, Rajani ^a   Tewari, Mallika ^a   Kumar, Mohan ^a   Singh, Alok K ^b   Shukla, Hari S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Apoptosis; cell cycle arrest; DNA repair; gallbladder cancer; tumour suppressor gene

Indexed keywords

ATM PROTEIN; CASEIN KINASE I; CASEIN KINASE II; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; CYCLIN E; DNA DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEOTIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE R; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN;

APOPTOSIS; CARCINOMA IN SITU; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; DNA DAMAGE; DNA REPAIR; DYSPLASIA; GALLBLADDER CANCER; GENE ACTIVATION; GENE CONTROL; GENE FUNCTION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; INVASIVE CARCINOMA; MUTATION; PRIORITY JOURNAL; REVIEW; TELOMERE;

APOPTOSIS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; GALLBLADDER NEOPLASMS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79551521139     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328341e371     Document Type: Review

References (99)

1. Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, et al. (1996). p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 43:521-526.
2. Arevalo F, Arias Stella C, Monge E (2007). Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder. Rev Esp Enferm Dig 99:694-697.
3. Attardi LD, Jacks T (1999). The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 55:48-63.
4. Billo P, Marchegiani C, Capella C, Sessa F (2000). Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa. Pathologica 92:249-256.
5. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, et al. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068.
6. Blagosklonny MV (2000). p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 14:1901-1907.
7. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z (2000). SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101:753-762.
8. Caelles C, Helmberg A, Karin M (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223.
9. Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH (2007). Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326-335.
10. Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS (2006). Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients. Manuscript id: 8962091628764582. BMC Cancer 6:126.
11. Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K, et al. (2004). Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28:995-1000.
12. Coultas L, Strasser A (2003). The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 13:115-123.
13. Da Rocha AO, Coutinho LM, Scholl JG, Leboutte LD (2004). The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepatogastroenterology 51:1310-1314.
14. Dhir V, Mohandas KM (1999). Epidemiology of digestive tract cancers in India IV: Gallbladder and pancreas. Indian J Gastroenterol 18:24-28.
15. Freedman DA, Levine AJ (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18:7288-7293.
16. Fu L, Minden MD, Benchimol S (1996). Translational regulation of human p53 gene expression. EMBO J 15:4392-4401.
17. Fujii K, Yokozaki H, Yasui W, Kuniyasu H, Hirata M, Kajiyama G, Tahara E (1996). High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Biomarkers Prev 5:461-466.
18. Giaccia AJ, Kastan MB (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973-2983.
19. Goldin RD, Roa JC (2009). Gallbladder cancer: a morphological and molecular update. Histopathology 55:218-229.
20. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G (1996). K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 77:452-458.
21. Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, et al. (1997). TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer 33:1136-1140.
22. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
23. Harris CC (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455.
24. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA (1995). A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305-311.
25. Haupt S, Berger M, Goldberg Z, Haupt Y (2003). Apoptosis - the p53 network. J Cell Sci 116:4077-4085.
26. He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, et al. (2005). Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 24:2929-2943.
27. Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogues JM, et al. (2004). Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford) 6:174-180.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science 253:49-53.
29. Hussain SP, Hollstein MH, Harris CC (2000). p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 919:79-85.
30. Indian Council of Medical Research (1996). Annual report of population based cancer registries of the national cancer registry programme 1993. New Delhi: ICMR Publication; pp. 18.
31. Itoi T,Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T (1997). Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Pathol Int 47:525-530.
32. Kalekou H, Miliaras D (2004). Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol 19:812-818.
33. Kanthan R, Radhi JM, Kanthan SC (2000). Gallbladder carcinomas: an immunoprognostic evaluation of p53, Bcl-2, CEA and alpha-fetoprotein. Can J Gastroenterol 14:181-184.
34. Kieser A, Weich HA, Brandner G, Marmé D, Kolch W (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969.
35. Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP, et al. (2000). Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 275:23139-23145.
36. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH (2001). Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 8:1127-1132.
37. Kim WB, Han HJ, Lee HJ, Park SS, Song TJ, Kim HK, et al. (2009). Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer. Ann Surg Oncol 16:23-34.
38. Kimura A, Tsuchiya Y, Lang I, Zoltan S, Nakadaira H, Ajioka Y, Kiyohara C, (2008). Effect of genetic predisposition on the risk of gallbladder cancer in Hungary. Asian Pac J Cancer Prev 9:391-396.
39. Koda M, Yashima K, Kawaguchi K, Andachi H, Hosoda A, Shiota G, et al. (2003). Expression of Fhit, Mlh1, and p53 protein in human gallbladder carcinoma. Cancer Lett 199:131-138.
40. Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer 13:293-225.
41. Lakin ND, Jackson SP (1999). Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655.
42. Larsson SC, Wolk A (2007). Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 96:1457-1461.
43. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C,Wistuba II, et al. (2001). Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51:349-364.
44. Legan M, Luzar B, Marolt VF, Cor A (2006). Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12:3425-3429.
45. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
46. Li DH, Zhang LQ, He FC (2008). Advances on mutant p53 research. Yi Chuan 30:697-703.
47. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
48. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP (1986). Human p53 gene localized to short arm of chromosome 17. Nature 319:783-794.
49. Mishra PK, Jatawa SK, Raghuram GV, Pathak N, Jain A, Tiwari A, et al. (2009). Correlation of aberrant expression of p53, Rad50, and cyclin-E proteins with microsatellite instability in gallbladder adenocarcinomas. Genet Mol Res 8:1202-1210.
50. Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, et al. (2000). Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 26:164-167.
51. Momand J, Wu HH, Dasgupta G (2000). MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242:15-29.
52. Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF (2005). TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 4:192-199.
53. Nagahashi M, Ajioka Y, Lang I, Szentirmay Z, Kasler M, Nakadaira H, et al. (2008). Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. World J Gastroenterol 14:70-75.
54. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. (2006). The clinical value of somatic T53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167.
55. Olivier M, Petitjean A, Marcel V, Pé tré A, Mounawar M, Plymoth A, et al. (2009). Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16:1-12.
56. Onoyama H, Yamamoto M, Takada M, Urakawa T, Ajiki T, Yamada I, et al. (1999). Diagnostic imaging of early gallbladder cancer: retrospective study of 53 cases. World J Surg 23:708-712.
57. Parwani AV, Geradts J, Caspers E, Offerhaus GJ, Yeo CJ, Cameron JL, et al. (2003). Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol 16:299-208.
58. Puhalla H, Kandioler D, Ludwig C, Filipits M,Wrba F, Laengle F, et al. (2004). p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res 24:1201-1206.
59. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC (2001). Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 19:380-383.
60. Rai A, Mohapatra SC, Shukla HS (2004). A review of association of dietary factors in gallbladder cancer. Indian J Cancer 41:147-152.
61. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591-1602.
62. Reisman D, Loging WT (1998). Transcriptional regulation of the p53 tumor suppressor gene. Semin Cancer Biol 8:317-324.
63. Roa I, Villaseca M, Araya J, Roa J, De Aretxabala X, Melo A, et al. (1997). p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 31:226-230.
64. Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X (2000). P53 gene mutation in gallbladder cancer. Rev Med Chil 128:251-258.
65. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT (1999). SUMO-1 modification activates the transcriptional response of p53. EMBO J 18:6455-6461.
66. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20:8458-8467.
67. Saetta AA (2006). K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol 93:644-649.
68. Saetta A, Lazaris AC, Michalopoulos NV, Davaris PS (2001). Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. Hepatogastroenterology 48:1284-1288.
69. Saetta AA, Gigelou F, Papanastasiou PI, Koilakou SV, Kalekou-Greca H, Miliaras D, et al. (2006). High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol 80:67-71.
70. Scoumanne A, Chen X (2008). Protein methylation: a new mechanism of p53 tumor suppressor regulation. Histol Histopathol 23:1143-1149.
71. Sessa F, Furlan D, Genasetti A, Billo P, Feltri M, Capella C (2003). Microsatellite instability and p53 expression in gallbladder carcinomas. Diagn Mol Pathol 12:96-102.
72. Shu KX, Li B,Wu LX (2007). The p53 network: p53 and its downstream genes. Colloids Surf B Biointerfaces 55:10-18.
73. Shukla HS, Avasthi K, Naithani YP (1981). A clinico-pathological study of the carcinoma gallbladder. Ind J Cancer 18:198-201.
74. Smith ML, Seo YR (2002). p53 regulation of DNA excision repair pathways. Mutagenesis 17:149-156.
75. Soussi T, May P (1996). Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 260:623-637.
76. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC (2003). TP53 and liver carcinogenesis. Hum Mutat 21:201-216.
77. Stancu M, Caruntu ID, Sajin M, Giuşca S, Badescu A, Dobrescu G (2007). Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer. Rev Med Chir Soc Med Nat Iasi 111:734-743.
78. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007). Mutant p53: an oncogenic transcription factor. Oncogene 26:2212-2219.
79. Takagawa M, Muguruma N, Oguri K, Imoto Y, Okamoto K, Ii K, et al. (2005). Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry. Dig Dis Sci 50:1410-1413.
80. Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R, Yamamoto M (1994). Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med 172:283-289.
81. Tewari M (2006). Contribution of silent gallstones in gallbladder cancer. J Surg Oncol 93:629-632.
82. Tian Y, Ding RY, Zhi YH, Guo RX,Wu SD (2006). Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 12:415-419.
83. Toledo F, Wahl GM (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923.
84. Toledo F, Wahl GM (2007). MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39:1476-1482.
85. Tsuchiya Y, Kiyohara C, Sato T, Nakamura K, Kimura A, Yamamoto M (2007). Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem 40:881-886.
86. Valenzuela MT, Guerrero R, Nunez MI, Ruiz De Almodovar JM, Sarker M, De Murcia G (2002). PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 21:1108-1116.
87. Vogelstein B, Kinzler KW(1992). p53 function and dysfunction. Cell 70:523-526.
88. Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604.
89. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283.
90. Waldman T, Kinzler KW, Vogelstein B (1995). p21 is necessary for the p53- mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190.
91. Wallace-Brodeur RR, Lowe SW (1999). Clinical implications of p53 mutations. Cell Mol Life Sci 55:64-75.
92. Wang SN, Chung SC, Tsai KB, Chai CY, Chang WT, Kuo KK, et al. (2006). Aberrant p53 expression and the development of gallbladder carcinoma and adenoma. Kaohsiung J Med Sci 22:53-59.
93. Washington K, Gottfried MR (1996). Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 16:99-104.
94. Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. (1995). Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 55:2511-2515.
95. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J (1996). p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 27:360-365.
96. Wu X, Bayle JH, Olson D, Levine AJ (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132.
97. Xuan YH, Choi YL, Shin YK, Kook MC, Chae SW, Park SM, et al. (2005). An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol 20:59-66.
98. Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, et al. (1998). Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 7:297-301.
99. Zhou J, Ahn J,Wilson SH, Prives C. A role for p53 in base excision repair. EMBO J (2001); 20:914-923.